Viral and non-viral gene therapy partially prevents experimental cisplatin-induced neuropathy

Gene Therapy

Volumn 9, Issue 19, 2002, Pages 1333-1337

  Pradat, P F ^a   Kennel, P ^b   Naimi Sadaoui, S ^b   Finiels, F ^b   Scherman, D ^b   Orsini, C ^b   Delaere, P ^b   Mallet, J ^a   Revah, F ^b,c  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SANOFI   (France)

^c CEREP   (France)

Author keywords

Adenovirus; Cisplatin; Gene therapy; Neuropathy; NT 3; Plasmid

Indexed keywords

ADENOVIRUS VECTOR; CISPLATIN; NEUROTROPHIN 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD FLOW; BODY WEIGHT; CELL SURVIVAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG TOLERABILITY; ELECTROPHYSIOLOGY; ELECTROPORATION; EXPERIMENTAL MODEL; GENE TRANSFER; IN VIVO STUDY; KIDNEY FUNCTION; MOUSE; MUSCLE DISEASE; NERVE FIBER; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; SENSORY NERVE CELL; SENSORY NEUROPATHY; SURVIVAL; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; ELECTROPORATION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; MICE; NEUROTROPHIN 3; SENSATION DISORDERS;

ADENOVIRIDAE; ANIMALIA; DNA VIRUSES;

EID: 0036790466     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301801     Document Type: Article

References (31)

1. Thompson SW, Davis LE, Kornfeld M, Hilgers RD, Standefer JC. Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer 1984; 54: 1269-1275.
2. DiStefano PS et al. The neurotrophins BDNF, NT-3 and NGF display distinct patterns of retrograde axonal transport in peripheral and central neurons. Neuron 1992; 8: 983-993.
3. Gregg RW et al. Cisplatin neurotoxicity: The relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol 1992; 10: 795-803.
4. Olsson Y. Vascular permeability in the peripheral nervous system. In: Dyck PJ et al (ed.). Peripheral Neuropathy. WB Saunders: Philadelphia, 1984, pp 579-597.
5. Gao WQ et al. Neurotrophin-3 reverses experimental cisplatin-induced peripheral sensory neuropathy. Ann Neurol 1995; 38: 30-37.
6. Helgren ME et al. Neurotrophin-3 administration attenuates deficits of pyridoxine-induced large-fiber sensory neuropathy. J Neurosci 1997; 17: 372-382.
7. Poduslo JF, Curran GL. Permeability at the blood-brain and blood-nerve barriers of the neurotrophic factors: NGF, CNTF, NT3, BDNF. Mol Brain Res 1996; 36: 280-286.
8. Pradat PF et al. Partial prevention of cisplatin-induced neuropathy by electroporation-mediated nonviral gene transfer. Hum Gene Ther 2001; 12: 367-375.
9. Haase G et al. Gene therapy of murine motor neuron disease using adenoviral vectors for neurotrophic factors. Nat Med 1997; 3: 429-436.
10. Pradat PF et al. Continuous delivery of NT-3 by gene therapy has a neuroprotective effect in experimental models of diabetic and acrylamide neuropathies. Hum Gene Ther 2001; 12: 2237-2249.
11. Chattopadhyay M et al. In vivo gene therapy for pyridoxine-induced neuropathy by herpes simplex virus-mediated gene transfer of neurotrophin-3. Ann Neurol 2002; 51: 19-27.
12. Windebank AJ. Use of growth factors in the treatment of motor neuron diseases. Adv Neurol 1995; 68: 229-234.
13. Rodriguez-Pena A, Botana M, Gonzalez M, Requejo F. Expression of neurotrophins and their receptors in sciatic nerve of experimentally diabetic rats. Neurosci Lett 1995; 200: 37-40.
14. Ihara C et al. Decreased neurotrophin-3 expression in skeletal muscles of streptozotocin-induced diabetic rats. Neuropeptides 1996; 30: 309-312.
15. Rodriguez-Pena A, Botana M, Gonzalez M, Requejo F. Expression of neurotrophins and their receptors in sciatic nerve of experimentally diabetic rats. Neurosci Lett 1995; 200: 37-40.
16. McMahon SB, Priestley JV. Peripheral neuropathies and neurotrophic factors: animal models and clinical perspectives. Curr Opin Neurobiol 1995; 5: 616-624.
17. Cavaletti G et al. Neuroprotectant drugs in cisplatin neurotoxicity. Anticancer Res 1996; 16: 3149-3160.
18. Oh SJ. Clinical Electromyography: Nerve Conduction Studies. In: 2nd edn. Williams& Wilkins: Baltimore, 1993.
19. Schmalbruch H, Krarup C. Animal models of neuropathy. Baillieres Clin Neurol 1996; 5: 77-105.
20. Verdu E et al. Physiological and immunohistochemical characterization of cisplatin-induced neuropathy in mice. Muscle Nerve 1999; 22: 329-340.
21. Dai Y et al. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci USA 1995; 92: 1401-1405.
22. Aihara H, Miyazaki J. Gene transfer into muscle by electroporation in vivo. Nat Biotechnol 1998; 16: 867-870.
23. Maruyama H et al. Continuous erythropoietin delivery by muscle-targeted gene transfer using in vivo electroporation. Hum Gene Ther 2000; 11: 429-437.
24. Herzog RW et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med 1999; 5: 56-63.
25. Muramatsu T et al. In vivo gene electroporation in skeletal muscle with special reference to the duration of gene expression. Int J Mol Med 2001; 7: 37-42.
26. Apfel SC et al. Nerve growth factor administration protects against experimental diabetic sensory neuropathy. Brain Res 1994; 634: 7-12.
27. Yuen EC, Mobley WC. Therapeutic applications of neurotrophic factors in disorders of motor neurons and peripheral nerves. Mol Med Today 1995; 1: 278-286.
28. Apfel SC. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: a randomized controlled trial. JAMA 2000; 284: 2215-2221.
29. Wolfe D, Goins WF, Kaplan TJ. Herpesvirus-mediated systemic delivery of nerve growth factor. Mol Ther 2001; 3: 61-69.
30. Simovic D et al. Improvement in chronic ischemic neuropathy after intramuscular phVEGF165 gene transfer in patients with critical limb ischemia. Arch Neurol 2001; 58: 761-768.
31. Crouzet J et al. Recombinational construction in Escherichia coli of infectious adenoviral genomes. Proc Natl Acad Sci USA 1997; 94: 1414-1419.